Skip to main content

Advertisement

Table 2 The most frequent moderately-late side effects recorded

From: IMRT sparing of normal tissues in locoregional treatment of breast cancer

Moderately-late side effects
Adverse events Grade Baseline 3 months 6 months 12 months 18 months 24 months 30 months
30 pts 30 pts 30 pts 29 pts 28 pts 27 pts 26 pts
Erythema pigmentation Grade 0   6 14 18 22 23 22
Grade1   23 16 11 6 4 4
Grade2   1 0 0 0 0 0
Induration fibrosis Grade 0   23 23 22 24 23 22
Grade 1   6 6 7 4 4 4
Grade 2   1 1 0 0 0 0
Telangiectasia Grade 0   30 30 29 26 23 21
  Grade 1   0 0 0 2 4 4
  Grade 2   0 0 0 0 0 1
Breast/chest wall pain Grade 0 23 13 16 17 18 20 20
Grade 1 6 16 13 12 9 6 6
Grade 2 1 0 1 0 1 1 0
Grade 3 0 1 0 0 0 0 0
Cough/dyspnea Grade 0 27 28 28 26 25 26 26
Grade 1 3 2 2 3 2 1 0
MSK upper limb treated/neurosensitive symptoms Grade 0 18 24 25 25 25 25 26
Grade 1 10 5 4 4 3 3 1
Grade 2 2 1 1 0 0 0 0
  1. The only grade 2 reported at 30 months is a cosmetic one. Note that the number of grade 1 toxicity is low at 30 months, with significant decreased number over time for pain and skin erythema/pigmentation.
  2. We can note that the number of grade 1 or 2 side effects for cough/dyspnea and neuro-muscular symptoms are not very significantly different between baseline and early follow-up assessments.
  3. MSK: musculoskeletal.